Novocure has developed technology that uses alternating electric fields to disrupt the proliferation of cancer cells. The low-intensity electric fields disrupt cellular processes critical to rapidly dividing cancer cells, thereby treating tumors while minimizing damage to healthy tissue. The FDA approved a device based on the technology, NovoTTF-100A, to treat glioblastoma multiforme, or GBM, brain tumors in 2011.

Subsequent authorizations expanded the eligible GBM population, moved Novocure into new indications and covered updated versions of the technology. Novocure expanded into locally advanced pancreatic cancer by testing the technology with the chemotherapy drugs gemcitabine and nab-paclitaxel.